Varnimcabtagene autoleucel (ARI‑00001) in relapsed or refractory mantle cell lymphoma
TP53 disruption remains the major adverse factor, associated with poor outcomes despite new combination therapies.
Bizonyítékszint: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.
Kapcsolódó jelek
- Mantle Cell Lymphoma: Are New Therapies Changing the Standard of Care?
- Hairy Cell Leukemia: Clinical Characteristics and Outcomes from a Single Center in the Middle East and North Africa
- Advances in biomarkers for mantle cell lymphoma in the era of targeted therapies
- Mantle Cell Lymphoma
- Lisocabtagene Maraleucel in Relapsed/Refractory Mantle Cell Lymphoma (MCL): Primary Analysis of the MCL Cohort From TRANSCEND NHL 001, a Phase I Multicenter Seamless Design Study